What was recalled
The U.S. Food and Drug Administration (FDA) has issued a Class I recall involving Baxter Healthcare Corporation, a major pharmaceutical manufacturer based in Deerfield, Illinois. This specific action targets a high-concentration intravenous fluid product known as Dextrose Injection, USP 70%. The affected items are packaged in large, 2000 mL bags designed for prescription-only use (Rx Only). Because this is a Class I recall, the FDA has determined that using or being exposed to this product could cause serious adverse health consequences or death. It represents the most critical level of recall classification, indicating that the hazard present in these specific batches is not merely an inconvenience but a direct threat to patient safety.
The precise scope of this recall is defined by several specific identifiers that must be matched exactly. The product bears the National Drug Code (NDC) 00338-0719-06. It is associated with Lot Number Y495066, which carries an expiration date of July 31, 2027. Although the product is manufactured in the United States by Baxter Healthcare Corporation located at 60016 Deerfield, IL, the distribution pattern for this recall covers the entire nation. This means that hospitals, clinics, pharmacies, and other medical facilities across all U.S. states may possess these bags, not just those in Illinois where the company is headquartered.
The recall was officially initiated on August 17, 2026. At the time of this announcement, the specific number of units involved in the recall was not stated by the agency. However, the nature of the defect—particulate matter identified as stainless steel particles within the solution—means that every single bag from the affected lot is considered compromised. Dextrose 70% is a potent hypertonic solution typically used in clinical settings for patients who require high-calorie intravenous nutrition or for managing fluid balance in critical care situations. The presence of any foreign material, particularly metal particles, in such a concentrated solution introduces a severe risk of embolism, infection, or vascular damage when administered directly into the bloodstream. Therefore, the recall is absolute and applies to all units from Lot Y495066 with NDC 00338-0719-06, regardless of where they are currently stored or who holds them.
If you work in a medical environment, it is crucial to understand that this recall is not limited to a single facility. Because the distribution was nationwide, inventory checks must be performed across all locations that may have received stock from Baxter during the production window for Lot Y495066. The urgency of this situation stems from the fact that these bags are prescription-only items, meaning they are handled by trained medical professionals who administer them directly to patients. Any delay in identifying and removing these specific bags from inventory could result in a patient receiving fluid contaminated with stainless steel particles, leading to potentially fatal outcomes.
The hazard, explained
When we talk about a Class I drug recall involving particulate matter, particularly metallic particles like stainless steel, we are dealing with a very specific type of physical contamination that occurs within the manufacturing or filling process. In this instance, the FDA has identified that tiny fragments of stainless steel have ended up inside the Dextrose Injection bags. To understand why this is so serious, we need to look at what happens when these particles enter the body through an intravenous (IV) line.
First, it is important to recognize that IV fluids are designed to go directly into your bloodstream, bypassing many of the body’s natural filtration systems. Normally, if you swallow something with small impurities, your digestive system can handle or filter them out. But when particulate matter enters a vein, those particles travel immediately with the flow of blood. Stainless steel particles, even when microscopic, are solid, sharp-edged, and biologically inert in a way that the body cannot break down or absorb. This means they remain in circulation until they lodge somewhere in your vascular system.
The primary danger here is mechanical obstruction and tissue damage. As these tiny metal fragments move through smaller blood vessels, they can get stuck, blocking the flow of oxygen-rich blood to critical tissues. This is known as embolization. If a particle blocks a vessel in the lungs, it can cause a pulmonary embolism; if it blocks a vessel in the brain, it can lead to a stroke. Even if the particles do not cause an immediate blockage, they can trigger inflammation. The body recognizes these foreign objects and sends immune cells to attack them, leading to local swelling, pain, and potentially more widespread inflammatory responses.
Additionally, stainless steel is not entirely biocompatible in this context. While it is strong and durable for medical devices, fragments left inside the body can irritate the lining of the blood vessels (the endothelium). This irritation can promote clot formation, increasing the risk of thrombosis. Over time, these particles can also accumulate in organs like the liver and spleen, which act as filters for the blood, potentially causing long-term granulomatous reactions where the body walls off the foreign material with scar tissue.
In general medical safety terms, any particulate contamination in injectable drugs is considered a severe hazard because it introduces an unpredictable variable into a sterile, controlled environment. The size of the particles matters; larger fragments cause immediate blockages, while smaller ones may travel further but still pose significant risks of micro-trauma to blood vessel walls. Because this recall involves Dextrose Injection, which is often used for hydration and nutrition in vulnerable patients, the presence of these stainless steel contaminants is particularly concerning. It compromises the very purpose of the treatment—supporting patient health—by introducing a direct threat to vascular integrity and systemic circulation.
Who is most at risk
When we look at who is truly vulnerable in this specific recall involving Baxter Healthcare’s Dextrose Injection, USP 70%, it is important to first clarify that the users of this medication are not typical consumers walking into a pharmacy. This is a prescription-only intravenous fluid used primarily in hospital settings, intensive care units, and clinical laboratories. Therefore, the people "at risk" here are patients who are currently receiving or have recently received treatment involving these specific 2000 mL bags. The hazard stems from the presence of particulate matter—specifically identified as stainless steel particles—within the solution. While any foreign object in an IV line is concerning, the nature of this contaminant and the method of delivery create distinct risks for particular patient populations.
The primary group at risk consists of patients with compromised vascular systems or those undergoing procedures that require large volumes of fluid. Because the recalled product involves 2000 mL bags, it is typically used in scenarios where significant hydration or nutrient delivery is needed over a period of time. If these stainless steel particles enter the bloodstream, they can cause mechanical obstruction in small blood vessels. For patients with existing heart conditions, particularly those with weakened hearts or poor circulation, even microscopic emboli (clots or blockages) can strain the cardiovascular system more than it would in a healthy individual. The risk is not just about the immediate irritation but potential long-term damage to capillary beds in critical organs.
Elderly patients and those with fragile blood vessels are also of particular concern. As people age, their vascular walls become more delicate and less elastic. The introduction of rigid metallic particles can cause micro-trauma to these vessels, potentially leading to inflammation or blockage in smaller arterioles. This is especially dangerous for individuals who may already have reduced kidney function or diabetes-related vascular issues, as their bodies are less equipped to filter out such debris. Furthermore, patients who are immunocompromised—such as those undergoing chemotherapy or organ transplant recipients—are at a higher risk because any introduction of foreign material can trigger severe inflammatory responses that their weakened immune systems might struggle to manage.
Another critical group includes neonates and pediatric patients in intensive care. While the specific lot mentioned (Y495066) is distributed nationwide, infants have much smaller blood volumes and narrower capillaries than adults. A particle that might be negligible in an adult could cause a significant blockage in a newborn’s delicate circulatory system. Therefore, healthcare providers treating very young patients must be especially vigilant. The risk here is not just about the immediate physical presence of the steel but the potential for it to lodge in critical areas like the lungs or brain, where blood flow is too narrow to allow such particles to pass through safely.
Finally, we must consider the logistical aspect of who holds the power to prevent harm. The actual patients are often unaware of the specific lot numbers of their IV fluids. Thus, the "at-risk" group also extends to healthcare workers and pharmacists who handle these bags. If they do not check the NDC (00338-0719-06) and Lot number against the recall list, the risk transfers directly to the patient at the bedside. The vulnerability lies in the gap between the manufacturer’s error and the clinical verification process. Ensuring that every bag is accounted for before it reaches a patient’s arm is the most crucial step in protecting this diverse group of individuals.
How to tell if you have the recalled item
When dealing with a Class I medical device or drug recall, such as this one involving Baxter Healthcare Corporation, precision is your best friend. Because this involves a specific intravenous solution used in clinical settings, you do not need to guess or rely on general descriptions. The FDA recall notice provides exact identifiers that make verification straightforward if you know where to look. Your first step is to locate the physical packaging of the Dextrose Injection, USP, 70% bag. These are large, 2000 mL bags, which are typically hung on IV poles in hospitals, clinics, or long-term care facilities. The critical information is printed directly on the label of the bag itself, not just on the outer shipping box.
The most important detail to verify is the National Drug Code (NDC). This unique identifier is a three-segment number that acts like a fingerprint for the product. For this specific recall, you must look for NDC 00338-0719-06. If your bag does not have this exact code, it is not part of this particular recall batch. Alongside the NDC, you must check the Lot Number. The recalled lot is identified as Y495066. It is crucial to check both the NDC and the Lot Number together, as other batches from the same manufacturer may be safe and unaffected by this specific issue involving particulate matter.
Once you have located these numbers on the label, confirm the expiration date to ensure your records align with the recalled item's timeline. The recalled bags have an expiration date of July 31, 2027. While the expiration date alone does not confirm a recall, it helps narrow down the possibilities if you are conducting a broad inventory check. Additionally, verify that the product is indeed "Rx Only" and manufactured by Baxter Healthcare Corporation in Deerfield, IL. The label should clearly state "Made in USA."
If you are a patient or a caregiver rather than a healthcare professional, it is highly unlikely you will encounter this item directly, as 70% Dextrose Injection is a high-concentration solution used primarily in hospital settings for parenteral nutrition. However, if you work in a medical facility, immediately isolate any bags matching NDC 00338-0719-06 and Lot Y495066. Do not use them under any circumstances. The presence of stainless steel particles is a serious physical hazard that can cause harm if infused into the bloodstream. If you are unsure about the status of your inventory, contact your pharmacy director or recall coordinator to cross-reference your stock against this list. When in doubt, remember that the combination of the specific NDC and Lot Number is the definitive proof of whether an item is affected.
What to do — step by step
If you are involved in the administration of intravenous fluids and believe you may have received one of the recalled Dextrose Injection, USP, 70%, bags from Baxter Healthcare Corporation, it is critical to act with both urgency and precision. The FDA has classified this recall as a Class I event, which represents the highest level of concern because exposure to the product could result in serious health consequences or death. However, the official recall documentation provided by the agency does not explicitly state the specific remedy, such as whether you should return the product for a full refund, exchange it for a safe replacement, or simply discard it. Because this critical instruction is missing from the available facts, you must rely on standard medical safety protocols and direct communication with healthcare providers to determine the correct course of action. Do not assume that the absence of a stated remedy means the situation is low-risk; rather, treat every step below as essential due diligence to protect patient health. First, immediately stop using any Dextrose Injection, USP, 70%, 2000 mL bags that match the recalled lot number Y495066 with an expiration date of July 31, 2027. This product contains particulate matter identified as stainless steel particles within the solution. Introducing metal fragments into a patient’s bloodstream can lead to embolisms, organ damage, or other severe systemic reactions. Do not attempt to filter the solution yourself, as this is not a safe or reliable method for removing microscopic metallic contaminants from an intravenous line. If you are a healthcare provider, isolate any remaining stock of this specific lot from your inventory immediately to prevent accidental administration. Label these bags clearly as "RECALLED - DO NOT USE" and store them in a secure area separate from active medications to avoid confusion during clinical emergencies. Second, contact the patient’s primary care physician or the hospital pharmacy director right away if any of these bags have already been administered. Even if no symptoms are currently visible, the presence of stainless steel particles requires professional medical evaluation. The healthcare team may need to monitor the patient for signs of embolization, inflammation, or other adverse reactions associated with particulate matter in the blood. Document exactly when and how much of the recalled product was used, as this information will be vital for medical records and potential follow-up care. If you are a consumer asking on behalf of a patient, encourage them to seek immediate medical attention if they experience unexplained pain, swelling, or difficulty breathing after receiving the infusion. Third, reach out to Baxter Healthcare Corporation directly to inquire about their specific instructions for this recall. Since the FDA summary does not specify whether a refund, repair, or replacement is offered, the manufacturer is the only entity that can provide definitive guidance on how to dispose of the product safely and whether financial compensation will be provided. You can typically find contact information for Baxter’s patient safety or quality assurance departments through their official corporate website or by calling their general customer service line. Ask specifically about the return process for lot Y495066 and request written confirmation of the steps you should take. If you are a hospital or clinic, your procurement department should handle this communication to ensure proper documentation and compliance with regulatory standards. Do not attempt to dispose of the recalled bags in regular trash without following hazardous medical waste protocols, as they remain a biohazard risk even if unused.Your refund, repair, or replacement options
When a recall of this magnitude occurs, the immediate question on everyone’s mind is often, “What do I get back for my trouble?” In the context of medical device and pharmaceutical recalls, particularly those classified as Class I by the FDA, the primary goal is not financial restitution in the traditional sense, but rather the immediate removal of hazardous products from the supply chain to protect patient health. For this specific recall involving Baxter Healthcare Corporation’s Dextrose Injection, USP, 70%, the official recall documentation does not explicitly state a standardized remedy such as a direct refund, repair, or automatic replacement program for individual consumers. This absence of a stated consumer-facing remedy is actually quite common in Class I drug recalls and requires a nuanced understanding of how these processes work behind the scenes.
It is crucial to understand that Dextrose Injection is an Rx-only medication, meaning it is not purchased directly by consumers from retail shelves like over-the-counter goods. Instead, it is distributed through a highly regulated network of hospitals, clinics, pharmacies, and healthcare providers. Therefore, the “remedy” in this scenario is primarily directed at these institutional partners rather than individual patients. Baxter Healthcare Corporation, headquartered in Deerfield, Illinois, is responsible for managing the recall logistics with these downstream customers. If you are a patient who has received this product, your interaction is likely with your healthcare provider or hospital pharmacy, not directly with Baxter’s consumer service line.
For healthcare facilities that have received the affected lots—specifically Lot #Y495066 with an expiration date of July 31, 2027—the standard procedure involves quarantining the inventory and coordinating with Baxter for its return or destruction. The company typically provides instructions for the safe disposal of the product or arranges for its collection to prevent it from being re-entered into the market. In many Class I recalls involving sterile injectables, the manufacturer may offer a credit or replacement stock once the contaminated units are verified as removed, but these terms are negotiated directly between Baxter and the distributing entities, not advertised publicly for general consumers.
If you suspect you have been affected by this recall, do not attempt to contact Baxter Healthcare Corporation expecting a personal refund check. Instead, your first step should be to contact the healthcare provider who administered or prescribed the medication. They are responsible for reporting any adverse events or suspected exposures to both their internal safety teams and the FDA’s MedWatch program. The provider will then liaise with Baxter’s quality assurance team to resolve the issue on a case-by-case basis. This might involve monitoring your health, providing alternative treatment at no cost, or issuing an invoice adjustment if the product was billed directly to you or your insurance before being recalled.
While a direct financial remedy is not explicitly outlined in the public recall notice, the value of your participation in this process lies in ensuring that the hazardous stainless steel particles are removed from use. This prevents potential serious health complications, such as embolisms or tissue damage, which would far outweigh any monetary cost of the drug itself. The “option” available to you is essentially peace of mind and safety assurance through proper medical follow-up. Always keep your records of any medications received during the period in question, as this will facilitate smoother communication with your provider if questions arise later regarding coverage or liability.
In summary, while there is no one-size-fits-all refund portal for this recall, the remedy is embedded in the regulatory framework that holds manufacturers accountable. Your role is to alert your medical team immediately. They will handle the logistical and financial reconciliation with Baxter Healthcare Corporation according to their internal contracts and FDA guidelines. This collaborative approach ensures that the focus remains squarely on patient safety rather than administrative paperwork.
What can happen if you ignore it
When a Class I recall involves an intravenous drug like Dextrose Injection, the stakes are exceptionally high because the product is being introduced directly into your bloodstream, bypassing the body’s natural filtration systems. If you or a patient continue to use this recalled Baxter Healthcare solution despite the identified hazard, the primary danger stems from the presence of stainless steel particulate matter within the 2000 mL bags. These are not microscopic contaminants that dissolve or pass harmlessly through; they are solid, foreign metal particles suspended in the fluid. Ignoring a recall of this nature is not merely a procedural oversight—it is a direct risk to vascular integrity and circulatory health.
The most immediate and severe consequence of infusing these particulates is mechanical obstruction. The stainless steel fragments can travel through the veins until they reach capillaries that are too narrow for them to pass. This can cause physical blockages in critical blood vessels, particularly in the lungs (pulmonary embolism), heart, or brain. Such blockages cut off oxygen supply to tissues, potentially leading to tissue death, stroke, or cardiac events. Even if the particles do not cause a complete blockage, they can trigger an inflammatory response as the immune system attempts to wall off and isolate the foreign material, leading to localized pain, swelling, and potential damage to the vein lining (phlebitis).
Beyond mechanical damage, there is the risk of systemic toxicity. Stainless steel contains various metals, including nickel, chromium, and iron. While these are generally biocompatible in solid implants, their presence as loose particulates in a high-volume infusion can lead to unexpected biological reactions. The body may react to the metal ions leaching from the particles, potentially causing allergic reactions in sensitive individuals or contributing to oxidative stress within the bloodstream. For patients with compromised kidney function, the inability to filter out these foreign bodies can exacerbate existing health conditions or lead to acute renal strain.
It is also crucial to understand that Dextrose Injection 70% is a hypertonic solution, typically used for specific medical needs such as providing calories and water in situations where oral intake is not possible. If the integrity of the bag is compromised by the presence of foreign matter, it may indicate broader manufacturing defects. Continuing to use this product could expose you to additional, unreported contaminants that were not identified in the initial recall notice. The risk is compounded by the volume of the product; a 2000 mL bag delivers a significant load of particulates directly into the central circulation over time.
Finally, ignoring a Class I recall undermines the safety net designed to protect public health. These recalls are initiated because the FDA has determined that using the product is likely to cause serious adverse health consequences or death. By continuing to use the recalled Dextrose Injection, you are bypassing the medical safeguards put in place by healthcare providers and regulators. The uncertainty of which other defects might exist in the batch, combined with the known presence of metal shards, creates a scenario where the potential for harm is both predictable and preventable. Do not wait for symptoms to appear; the damage from vascular particulates can be silent until it becomes critical.